Skip to main content

Table 5 Clinical studies of belinostat (PXD101)

From: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

Phase Other agent Disease (pt. No.) Schedule Recommended dose & response Reference
I   Advanced hematological neoplasms(16) Day 1 to 5 of a 21-day cycle 1000 mg/m2/d [128]
I AZA Advanced myeloid neoplasms(230 Days 1-5 of a 28 day cycle 1000 mg/m2 [129]
I   Advanced refractory solid tumors(46) Days 1-5 of a 21 day cycle 1000 mg/m2
SD 39%
[127]
II   relapsed malignant pleural mesothelioma(13) Days 1-5 of a 21 day cycle Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma [122]
II   Platinum resistant epithelial ovarian tumors(EOC,18) and micropapillary/borderline ovarian tumors(LMP,12) Days 1-5 of a 21 day cycle with 1000 mg/m2 EOC: SD 50%, PD25% N/E 25%; LMP: SD 75%, PR8.3%, N/E 16.6% [130]